OncoMatch/Clinical Trials/NCT06986174
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Is NCT06986174 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pacritinib for waldenström macroglobulinemia.
Treatment: Pacritinib — This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
absolute neutrophil count ≥0.5 k/uL without growth factor within 7 days; platelet count ≥50 k/uL without platelet transfusion within 7 days
Kidney function
Creatinine clearance ≥30 ml/min using Cockcroft/Gault equation
Liver function
total bilirubin ≤1.5x ULN or ≤3x ULN with documented liver involvement, hemolysis or Gilbert's disease; AST (SGOT) and ALT (SGPT) ≤2.5x ULN or ≤5x ULN with documented liver involvement
Cardiac function
Significant cardiovascular disease defined as: unstable angina, history of myocardial infarction within 6 months, LVEF ≤45% in prior 12 months, NYHA Class 3 or 4 cardiac disease, uncontrolled or symptomatic arrhythmias; Prolonged QT Interval with baseline QTc >480 msec using Bazette formula
Participants must meet the following organ and marrow functions as defined below: absolute neutrophil count ≥0.5 k/uL without growth factor within 7 days; platelet count ≥50 k/uL without platelet transfusion within 7 days; total bilirubin ≤1.5x ULN or ≤3x ULN with documented liver involvement, hemolysis or Gilbert's disease; AST (SGOT) and ALT (SGPT) ≤2.5x ULN or ≤5x ULN with documented liver involvement; Creatinine clearance ≥30 ml/min using Cockcroft/Gault equation; Significant cardiovascular disease defined as: unstable angina, history of myocardial infarction within 6 months, LVEF ≤45% in prior 12 months, NYHA Class 3 or 4 cardiac disease, uncontrolled or symptomatic arrhythmias; Prolonged QT Interval with baseline QTc >480 msec using Bazette formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06986174 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages